VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 10, 2009) - Advanced Proteome Therapeutics Corporation (the "Company") (TSX VENTURE: APC) announces that, pursuant to the Company's stock option plan, it has granted incentive stock options to an officer of the Company to purchase up to 300,000 common shares in the capital of the Company, exercisable on or before March 10, 2014 at a price of $0.27 per share. The option grant is subject to board approval and the vesting provisions contained in the Company's stock option plan.
APC's primary corporate mission is to apply its proprietary drug delivery and drug redevelopment technologies to produce new, improved versions of therapeutic proteins and pioneer the emerging field of protein-site targeting. The market for diagnostics and therapeutic proteins and peptides is expected to surpass more than 50 Billion USD by the year 2010 and is the fastest growing segment of the pharmaceutical market. Future growth however depends largely on the industry overcoming a number of hurdles, including drug delivery challenges and the need for homogeneous conjugates that APC is attempting to address.
ON BEHALF OF THE BOARD
Alexander (Allen) Krantz, President and Chief Executive Officer
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.